Until recently, curative options for patients experiencing
|
|
- Warren Hall
- 6 years ago
- Views:
Transcription
1 JOURNAL OF ENDOUROLOGY Volume 30, Number 6, June 2016 ª Mary Ann Liebert, Inc. Pp DOI: /end Imaging and Noninvasive Therapy Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen Evan Kovac, MD, CM, FRCSC, 1 Ahmed ElShafei, MD, PhD, 1,2 Kae Jack Tay, MBBS, MRCS, MMed, FAMS, 3 Melissa Mendez, MD, 3 Thomas J. Polascik, MD, FACS, 3 and J. Stephen Jones, MD, FACS, MBA 1 Abstract Background and Objectives: Salvage prostate cryoablation is an effective treatment for patients with localized prostate cancer relapse following primary radiotherapy. The postsalvage prostate-specific antigen (PSA) nadir that best predicts long-term biochemical progression-free survival (bpfs) is not yet defined. We sought to determine what nadir PSA best predicted success following salvage whole-gland cryoablation. Patients and Methods: We retrospectively reviewed a cohort of 486 hormone-naive patients who underwent salvage whole-gland cryoablation from the Cryo On-Line Database (COLD). Studied variables were age, race, initial PSA, presalvage prostate-specific antigen (pspsa), initial Gleason score, Gleason score at presalvage biopsy, clinical stage, and follow-up PSA values. Kaplan Meier (KM) analysis was used to calculate 5-year bpfs using the Phoenix criteria. Hazard ratio and relative risk were also analyzed. Differences among the KM estimates, at 5 years, were calculated using the log-rank test. Results: Using group thresholds, KM analysis identified nadir PSA less than or greater than 0.4 ng/ml as the nadir PSA threshold, with the greatest difference in bpfs. The KM estimated 5-year bpfs was 75.5% and 22.1% for nadir PSA <0.4 and 0.4 ng/ml, respectively. Stratified by pspsa, the KM estimated 5-year bpfs comparing patients with PSA nadir <0.4 vs 0.4 ng/ml was 78.5% and 17.9% ( p < ) for pspsa <4 ng/ml, 77.1% and 15.7% ( p < ) for pspsa 4 10 ng/ml, and 77.8% and 16.8% ( p < ) for pspsa >10 ng/ml, respectively. Conclusion: The best objective indicator of biochemical success following whole-gland salvage cryoablation of the prostate is PSA nadir <0.4 ng/ml. Introduction Until recently, curative options for patients experiencing biochemical recurrence (BR) after primary radiotherapy of the prostate cancer were limited. Salvage postradiation radical prostatectomy (RP) is the gold standard for local control, but in the postradiation scenario, it is historically fraught with significantly higher complication rates than in the primary setting. 1,2 Androgen deprivation therapy (ADT), while noninvasive, has significant systemic side effects in the mid to long term and is never given with curative intent. In the last decade, prostate cryotherapy has emerged as a reasonable salvage option for recurrent localized prostate cancer. 3 8 Salvage cryotherapy is minimally invasive and is an attractive option for patients with BR and who either wish to avoid or are not candidates for RP. However, while multiple models based on prostate-specific antigen (PSA) nadir and other kinetics have been extensively validated for prediction of long-term success after both salvage external beam radiotherapy and brachytherapy for recurrent prostate cancer, 9,10 models for modern salvage prostate cryoablation remain hampered by modest follow-up even in large cohorts. We previously reported on the prognostic value of the first PSA level <0.6 ng/ml following salvage cryoablation of the prostate for recurrent prostate cancer. 11 However, follow-up was limited to 36 months, and longitudinal PSA testing was not analyzed. Subsequently, we demonstrated that a first postcryo PSA of <0.4 ng/ml predicts improved BR rates in a primary cryotherapy setting for localized prostate cancer. 12 The discrepancy between ideal initial PSA values following primary and salvage prostate cryoablation has not yet been explained. In this article, with a larger cohort and longer follow-up, we sought to identify the 1 Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio. 2 Urology Department, Medical School, Cairo University, Giza, Egypt. 3 Division of Urology, Department of Surgery, Duke University Medical Center, Durham, North Carolina. 624
2 SALVAGE PROSTATE CRYOABLATION 625 best PSA nadir cut point to predict future BR in a salvage prostate cryotherapy cohort. Patients and Methods The Cryo On-Line Database (COLD) was used to identify patients who were referred for salvage, full-gland cryotherapy of the prostate following primary radiotherapy of localized prostate cancer. The Institutional Review Board approval was granted for the purposes of the analysis. The majority of patients (94%) had biopsy-proven prostate cancer recurrence before undergoing salvage cryotherapy, with the remainder (6%) having missing data from the registry (Table 1). Patients with salvage partial-gland or primary whole-gland cryotherapy were excluded, as well as those with incomplete follow-up. Patient serum testosterone (T) levels were not captured in COLD, and thus, patients with prior ADT were excluded from the final analysis as return to precastrate T levels could not be determined, even in patients with an adequate washout period. All patients received a metastatic evaluation in the form of, at minimum, a bone scan and chest X-ray. Patients with evidence of locally advanced or metastatic disease at the time of salvage cryotherapy were excluded from the analysis. We collected and analyzed baseline patient characteristics, including patient age, race, initial PSA, pre-rt Gleason score, total prostate volume, clinical T stage, PSA at diagnosis of recurrence, and postsalvage cryotherapy PSA values. The main endpoint measured was postsalvage cryotherapy BR, defined using the Phoenix criteria (PSA nadir +2) and in line with previous reports from the COLD registry Table 1. Patient Baseline Characteristics (N = 486) Variables Name in registry Number n % Age PI_AGE_AT_TREATMENT Min 46 Median 72 Mean SD 7.53 Max 93 Missing 0 Race PI_RACE African American Asian Caucasian Hispanic Other Missing PSA PI_SERUM_PSA Min 0 Median 4.7 Mean 6.09 SD 5.79 Max 64.2 Missing 6 Clinical T stage clinical.stage T1a T1b T1c T2a T2b T2c T3a T3b T3c T Gleason score category Total prostate volume PI_TOTAL_ GLEASON_SCORE PO_TOTAL_VOLUME Min 3.6 PSA = prostate-specific antigen; SD = standard deviation. Missing Missing Median 23 Mean SD 11.5 Max 92.2 Missing 226
3 626 KOVAC ET AL. Statistical analysis The Kaplan Meier (KM) method was used to calculate the 5-year biochemical progression-free survival (bpfs) after salvage cryotherapy. The log-rank test was used to calculate differences among KM estimates at 5-year follow-up between patients who reached various PSA nadir values and between subgroups of patients with various presalvage prostate-specific antigen (pspsa) values (<4, 4 10, and >10 ng/ml). The statistical method for identifying PSA cut point with the greatest difference in bpfs has been previously described. 12 Briefly, to identify the postsalvage PSA nadir cut point that best predicts bpfs, we analyzed increasing PSA nadir thresholds, beginning at 0.1 ng/ml and repeated at increments of 0.1 ng/ml until 10 ng/ml. At each threshold, a Kaplan Meier curve was calculated, and BR was analyzed for those with PSA nadir above and below the threshold, and p-values were calculated for the difference. The best cut point was identified when the rates of patients at risk of BR above and below the incremental threshold was largest. All statistical calculations were performed using R Results We identified 998 patients who were referred for salvage cryoablation of the prostate from the COLD registry. Of these, 512 were excluded (105 patients received partial-gland salvage cryotherapy, 325 patients received prior ADT, and 82 patients had incomplete or missing follow-up PSA information) (Fig. 1). In total, 486 patients were identified for the final analysis. Median patient age was 72 years. Mean and median pspsa was 6.09 and 4.7, respectively. The remaining baseline characteristics of our patient cohort are represented in Table 1. Median follow-up was 18.2 months (interquartile range: months). After systematically analyzing all possible thresholds for the greatest discrimination between bpfs time, we have FIG. 1. Breakdown of excluded patients for final analysis. ADT = androgen deprivation therapy. identified the best PSA nadir cut point to be 0.4 ng/ml. Comparing the discrimination between, for example, using cut points 0.4 and 1.0 ng/ml, 0.4 ng/ml had a sensitivity and specificity of 0.47 and 0.78, respectively, while a cut point 1.0 ng/ml had a sensitivity and specificity of 0.31 and 0.85, respectively. Therefore, using a cut point 0.4 ng/ml correctly identified those who experienced BR better than using a cut point 1.0 ng/ml. The calculated concordance statistics using cut points 0.4 and 1.0 ng/ml were 0.72 and 0.66, respectively ( p-value <0.0001). Figure 2 represents the KM estimated 5-year bpfs for patients who achieved a PSA nadir less than or greater than 0.4 ng/ml following salvage prostate cryotherapy. For patients who achieved a PSA nadir <0.4 ng/ml, 2- and 5-year estimated bpfs rates were 91.7% and 75.5%, respectively. Patients who achieved a PSA nadir 0.4 ng/ml had 2- and 5- year estimated bpfs rates of 50.8% and 22.1%, respectively. Our statistical analysis failed to identify a better or more reliable PSA nadir endpoint than 0.4 ng/ml. Figures 3 5 represent KM estimated bpfs curves for patients with pspsa values <4, 4 10, and >10 ng/ml, respectively, based on a PSA nadir cut point 0.4 ng/ml. We found significantly improved 5-year bpfs rates among patients who achieved a nadir PSA <0.4 ng/ml, regardless of pspsa level, and the results of this analysis are summarized in Table 2. Discussion Whole-gland cryotherapy of the prostate represents another potentially curative weapon in the urologist s armament for patients with biochemically recurrent localized prostate cancer following nonsurgical primary therapies, such as external beam radiotherapy, brachytherapy, highintensity focused ultrasound, and primary partial- or wholegland cryotherapy. In this study, we demonstrate that patients who undergo salvage cryotherapy can expect long-term bpfs if their postsalvage PSA nadir is <0.4 ng/ml. In addition, the significant improvement in bpfs was seen across all pspsa subgroups. To standardize the outcome analysis, we used the Phoenix definition to define BR. While originally validated to define BR in a postradiotherapy population, Pitman et al. demonstrated that nadir plus 2 ng/ml outperformed all other definitions of BR in a postcryoablation cohort with biopsyproven prostate cancer recurrence. 14 Our analyses stem from data collected through the COLD registry. While COLD data collection and reporting is voluntary, is variable from institution to institution, and represents heterogeneous operative techniques among reporting clinicians, it nevertheless represents an invaluable, multiinstitutional resource that has gathered pre- and posttreatment information on more than 6000 patients who have undergone partial- and whole-gland primary and salvage cryotherapy of the prostate. An important consideration for patients with biochemically recurrent prostate cancer following primary radiotherapy remains whether to undergo local salvage treatment versus systemic ADT. For patients with life expectancies >10 years and without radiographic evidence of metastases, longterm cure rates are often attained with salvage RP. 1 We believe that salvage prostate cryoablation represents a viable alternative to salvage RP, and previous studies have reported
4 SALVAGE PROSTATE CRYOABLATION 627 FIG. 2. Kaplan Meier estimated 5-year biochemical progression-free survival comparing PSA nadir <0.4 and 0.4 ng/ml. PSA = prostate-specific antigen. similar disease-specific survival rates following salvage RP and salvage cryotherapy. 15 The results of our analysis suggest that salvage cryoablation may be beneficial to patients with a wide range of pspsa values and who reach a postsalvage PSA nadir <0.4 ng/ml. Indeed, previous work on salvage cryotherapy has mainly focused on pretreatment predictors of success. Using the COLD registry, Spiess et al. constructed a predictive nomogram for biochemical failure in patients undergoing salvage cryotherapy based on several diagnostic variables, including FIG. 3. Kaplan Meier plot stratified by PSA nadir 0.4 ng/ml for patients with a pspsa <4 ng/ml. pspsa = presalvage prostate-specific antigen.
5 628 KOVAC ET AL. FIG. 4. Kaplan Meier plot stratified by PSA nadir 0.4 ng/ml for patients with a pspsa 4 10 ng/ml. serum PSA level at diagnosis, biopsy Gleason grade, and initial clinical T stage. 16 Later, Spiess et al. developed a risk stratification model for biochemical failure based on both pre- and postsalvage patient characteristics. That retrospective analysis, which comprised 132 patients, found that a PSA nadir >2.5 ng/ml significantly predicted postsalvage biochemical failure. 17 Our cohort comprised 486 patients and represents the largest cohort to date for the purposes of analyzing postsalvage cryotherapy bpfs. Thus, using predictive nomograms of success after salvage cryoablation will aid FIG. 5. Kaplan Meier plot stratified by PSA nadir 0.4 ng/ml for patients with a pspsa >10 ng/ml.
6 SALVAGE PROSTATE CRYOABLATION 629 Table 2. Kaplan Meier Five-Year Estimated Biochemical Progression-Free Survival Rates, Stratified by Presalvage Prostate-Specific Antigen Level and Based on a Prostate-Specific Antigen Nadir Cut Point 0.4 ng/ml PSA nadir (ng/ml) pspsa (ng/ml) < p-value Overall 75.5% 22.1% < <4 78.5% 17.9% < % 15.7% < > % 16.8% < pspsa = presalvage prostate-specific antigen. clinicians in selecting patients who are most likely to attain a postsalvage PSA nadir <0.4 ng/ml. We previously examined the prognostic importance of the initial posttreatment PSA value in a salvage cryotherapy setting for biochemically recurrent prostate cancer and showed that an initial postsalvage cryoablation PSA <0.6 ng/ml was also associated with improved bpfs rates at 36-month follow-up. 11 Later, however, we reported on prognostic implications of PSA nadir following primary, wholegland prostate cryoablation and found a PSA nadir <0.4 ng/ml to be both attainable (891 of 1111 [80%] patients) and predictive of excellent bpfs rates. 12 In the current study, we endeavored to expand on this finding by examining multiple PSA follow-up values over a longer time in a larger cohort following salvage prostate cryoablation and, again, found no better PSA nadir cut point than 0.4 ng/ml at a follow-up of 60 months. Thus, the results of the current study strengthen our previous findings in a primary cryoablation setting and reiterate the importance of reaching a postsalvage PSA nadir <0.4 ng/ml by demonstrating substantially improved bpfs rates at 5-year follow-up. In a subanalysis, we stratified patients by pspsa and found significantly better bpfs rates for patients who reached a postsalvage PSA nadir <0.4 ng/ml, regardless of pspsa. Patients with pspsa values <4, 4 10, and >10 ng/ml can expect 5-year bpfs rates of 78.5%, 77.1%, and 77.8%, respectively. The COLD registry-derived analyses of salvage cryotherapy outcomes based on pspsa are not without precedent. A previous report on outcomes after salvage prostate cryoablation stratified patients based on pspsa values less than and greater than 5.0 ng/ml. 18 Historically, the preferred salvage treatment for men with an intact prostate gland has been RP, and reports on salvage RP have demonstrated improved bpfs rates with pspsa levels below 10 ng/ml. 1,19 23 In many of these series, the pspsa level was the only significant pretreatment predictor of postsalvage disease progression. We believe that investigators of salvage RP have stratified biochemical outcomes by pspsa levels above or below 10 ng/ml due to the historical value at which PSA was regarded as abnormal. Even though such stratification is artificial, PSA values at or below this range, combined with other classifiers, such as Gleason score at recurrence, ostensibly represent recurrent, organ-confined disease. In this sense, pspsa can be used as a surrogate for organ-confined disease. We sought to present a similar stratification model, based on three different pspsa subgroups (<4.0, 4 10, and >10 ng/ml), and found significantly better bpfs for patients reaching a PSA nadir <0.4 ng/ml across all pspsa subgroups. As a salvage option, whole-gland cryotherapy is a relatively novel technology. Radiation, by comparison, is a much more established method of salvage for men who experience biochemical failure after primary surgical treatment of prostate cancer. For focal treatments to be widely accepted as a method of prostate cancer salvage, they must show comparable results compared with well-established salvage modalities. In a cohort of 448 men who received salvage radiation therapy without androgen deprivation for BR following RP, Jackson et al. demonstrated significantly improved distant metastases rates, cancer-specific survival, and overall survival with an undetectable postsalvage PSA nadir, whereas our cut point for significantly improved bpfs was 0.4 ng/ml. 24 Botticella et al. showed that PSA nadir was the only independent predictor of biochemical and clinical outcomes in a cohort of patients who underwent monotherapy salvage prostate radiotherapy for postprostatectomy BR. 25 Our results are consistent with salvage radiotherapy literature with regard to the importance of PSA nadir as a strong predictor of bpfs. In one of the largest meta-analyses of salvage prostate radiotherapy, 5-year bpfs rates ranged from 20% to 70%. 26 Based on our results, whole-gland salvage cryotherapy achieves equal, if not better, bpfs rates. However, BR is only one aspect of progression. This study establishes the starting point by defining short-term success with a nadir PSA cut point 0.4 ng/ml, but further studies are required to confirm whether this translates to improved metastasis-free, disease-specific, and overall survival rates. We believe it is important for clinicians to be able to offer patients an accurate estimation of future BR risk based on posttreatment PSA trends. In prostate cancer, an undetectable PSA post-rp is the best indicator of cure. Meanwhile, with radiation therapies (external beam, brachytherapy, etc.), an inverse relationship exists between PSA nadir and the chance of long-term cure, with no defined absolute cut point. We sought to identify a meaningful PSA nadir level postsalvage, whole-gland cryotherapy of the prostate at which the patient can expect a reasonable long-term BR-free state. To our knowledge, this is the largest study to identify an ideal target PSA nadir postsalvage cryotherapy, and that PSA value is 0.4 ng/ml, and translates to an overall, 5-year bpfs of 75.5%. Our study carries several limitations. First, the retrospective nature of our analysis lends itself to inherent biases. Second, postsalvage cryotherapy biopsy would be a more definitive proof of treatment success; however, this information is not reported in COLD. In addition, metastases rates, disease-specific survival rates, and overall survival rates were not included in the analysis. We believe that these endpoints are more meaningful and impactful to the patient and should be the focus of future studies. Statistically speaking, we performed a univariate analysis using the KM method to predict bpfs based on a PSA cut point 0.4 ng/ml but refrained from performing a multivariate Cox model based on additional factors, such as pspsa, presalvage Gleason score, prostate volume, age, race, and initial clinical T-stage. We believe that it is difficult to compare postsalvage PSA nadir with presalvage factors head-to-head as they are taken at two different time points. Therefore, adding postsalvage
7 630 KOVAC ET AL. cryotherapy PSA nadir into a predictive model using the same follow-up time as pspsa would bias the results to the longer surviving patients. Furthermore, we limited the number of patients in our cohort by excluding 254 non-adtnaive patients. In a recent study of patients with BR after pelvic radiation on intermittent ADT, full T recovery during nontreatment cycles occurred in only 35% of patients. 27 Since patient serum T levels are not recorded in COLD, T recovery could not be proven, even if a proportion of these patients experienced a significant washout period from ADT. Median follow-up following salvage cryotherapy was limited, at 18.2 months. Thus, the KM estimated bpfs data should be interpreted with caution. Finally, we did not stratify patients based on initial radiation dose. Due to improved biochemical failure rates with dose escalation regimens, 28 patients with BR after high-dose external beam radiotherapy might harbor more biologically aggressive disease than those who biochemically failed after conventional dose radiotherapy. Concordantly, bpfs rates for patients who achieve a PSA nadir <0.4 ng/ml may differ between these two relapsing groups. Nevertheless, the ability to reassure patients who reach a postsalvage cryotherapy nadir <0.4 ng/ml that their chances of remaining biochemically free of disease at 5 years range between 65% and 75% is meaningful to both urologist and patient. Conclusion Our analysis of the COLD registry patients who underwent whole-gland salvage cryotherapy of the prostate following primary radiotherapy for adenocarcinoma of the prostate demonstrates that patients who reach a postsalvage PSA nadir <0.4 ng/ml have significantly improved bpfs rates compared with those who reach a PSA nadir >0.4 ng/ml. Additionally, using a PSA nadir cut point 0.4 ng/ml significantly improved bpfs rates that were seen across all pspsa groups. Author Disclosure Statement Dr. J.S.J. is a consultant for Healthtronics. Dr. T.J.P. is a consultant and educator and has investment interests in Endocare. All other authors have no relevant conflicts of interest. References 1. Bianco FJ, Jr., Scardino PT, Stephenson AJ, Diblasio CJ, Fearn PA, Eastham JA. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005;62: Gotto GT, Yunis LH, Vora K, Eastham JA, Scardino PT, Rabbani F. Impact of prior prostate radiation on complications after radical prostatectomy. J Urol 2010;184: Kimura M, Mouraviev V, Tsivian M, Mayes JM, Satoh T, Polascik TJ. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int 2010; 105: Langenhuijsen JF, Broers EM, Vergunst H. Cryosurgery for prostate cancer: An update on clinical results of modern cryotechnology. Eur Urol 2009;55: Li YH, Elshafei A, Agarwal G, Ruckle H, Powsang J, Jones JS. Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: Initial results from the cryo on-line data registry. Prostate 2015;75: Marberger M. Energy-based ablative therapy of prostate cancer: High-intensity focused ultrasound and cryoablation. Curr Opin Urol 2007;17: Mouraviev V, Polascik TJ. Update on cryotherapy for prostate cancer in Curr Opin Urol 2006;16: Ritch CR, Katz AE. Prostate cryotherapy: Current status. Curr Opin Urol 2009;19: Blanchard P, Bakkour M, De Crevoisier R, Levy A, Baumert H, Patard JJ, et al. Early PSA level decline is an independent predictor of biochemical and clinical control for salvage postprostatectomy radiotherapy. Urol Oncol 2014;33:108e e Peters M, Maenhout M, van der Voort van Zyp JR, Moerland MA, Moman MR, Steuten LM, et al. Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: A retrospective study regarding toxicity, biochemical outcome and quality of life. Radiother Oncol 2014;112: Levy DA, Pisters LL, Jones JS. Prognostic value of initial prostate-specific antigen levels after salvage cryoablation for prostate cancer. BJU Int 2010;106: Levy DA, Ross AE, ElShafei A, Krishnan N, Hatem A, Jones JS. Definition of biochemical success following primary whole gland prostate cryoablation. J Urol 2014;192: Levy DA, Li J, Jones S. Impact of disease burden on cryoablation prostate-specific antigen outcomes. Urology 2010; 75: Pitman M, Shapiro EY, Hruby GW, Truesdale MD, Cheetham PJ, Saad S, et al. Comparison of biochemical failure definitions for predicting local cancer recurrence following cryoablation of the prostate. Prostate 2012;72: Pisters LL, Leibovici D, Blute M, Zincke H, Sebo TJ, Slezak JM, et al. Locally recurrent prostate cancer after initial radiation therapy: A comparison of salvage radical prostatectomy versus cryotherapy. J Urol 2009;182: ; discussion Spiess PE, Katz AE, Chin JL, Bahn D, Cohen JK, Shinohara K, et al. A pretreatment nomogram predicting biochemical failure after salvage cryotherapy for locally recurrent prostate cancer. BJU Int 2010;106: Spiess PE, Levy DA, Mouraviev V, Pisters LL, Jones JS. Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: A novel risk stratification model. BJU Int 2013;112:E256 E Spiess PE, Levy DA, Pisters LL, Mouraviev V, Jones JS. Outcomes of salvage prostate cryotherapy stratified by pretreatment PSA: Update from the COLD registry. World J Urol 2013;31: Amling CL, Lerner SE, Martin SK, Slezak JM, Blute ML, Zincke H. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol 1999;161: ; discussion Kaffenberger SD, Keegan KA, Bansal NK, Morgan TM, Tang DH, Barocas DA, et al. Salvage robotic assisted laparoscopic radical prostatectomy: A single institution, 5-year experience. J Urol 2013;189: Rogers E, Ohori M, Kassabian VS, Wheeler TM, Scardino PT. Salvage radical prostatectomy: Outcome measured by
8 SALVAGE PROSTATE CRYOABLATION 631 serum prostate specific antigen levels. J Urol 1995;153: Rosoff JS, Savage SJ, Prasad SM. Salvage radical prostatectomy as management of locally recurrent prostate cancer: Outcomes and complications. World J Urol 2013; 31: Sanderson KM, Penson DF, Cai J, Groshen S, Stein JP, Lieskovsky G, et al. Salvage radical prostatectomy: Quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol 2006;176: ; discussion Jackson WC, Johnson SB, Foster B, Foster C, Li D, Song Y, et al. Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. Pract Radiat Oncol 2014;4: Botticella A, Guarneri A, Levra NG, Munoz F, Filippi AR, Rondi N, et al. Biochemical and clinical outcomes after high-dose salvage radiotherapy as monotherapy for prostate cancer. J Cancer Res Clin Oncol 2014;140: Ohri N, Dicker AP, Trabulsi EJ, Showalter TN. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer 2012;48: Crook JM, O Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 367: Hou Z, Li G, Bai S. High dose versus conventional dose in external beam radiotherapy of prostate cancer: A metaanalysis of long-term follow-up. J Cancer Res Clin Oncol 2015;141: Address correspondence to: Evan Kovac, MD, CM, FRCSC Glickman Urological and Kidney Institute Cleveland Clinic 9500 Euclid Avenue, Mail Code Q10-1 Cleveland, OH kovace@ccf.org Abbreviations Used ADT ¼ androgen deprivation therapy bpfs ¼ biochemical progression-free survival BR ¼ biochemical recurrence COLD ¼ Cryo On-Line Database KM ¼ Kaplan Meier PSA ¼ prostate-specific antigen pspsa ¼ presalvage prostate-specific antigen RP ¼ radical prostatectomy SD ¼ standard deviation T ¼ testosterone
Disease-Free Survival Following Salvage Cryotherapy for Biopsy-Proven Radio-Recurrent Prostate Cancer
EUROPEAN UROLOGY 60 (2011) 405 410 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by J. Stephen Jones on pp. 411 412 of this issue
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationOncologic Outcome and Patterns of Recurrence after Salvage Radical Prostatectomy
european urology 55 (2009) 404 411 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Oncologic Outcome and Patterns of Recurrence after Salvage Radical Prostatectomy
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationTreatment Failure After Primary and Salvage Therapy for Prostate Cancer
307 Treatment Failure After Primary and Salvage Therapy for Prostate Cancer Likelihood, Patterns of Care, and Outcomes Piyush K. Agarwal, MD 1 Natalia Sadetsky, MD, MPH 2 Badrinath R. Konety, MD, MBA 2
More informationUroCryo Ablation CLINICAL DATA REVIEW HealthTronics, Inc. All rights reserved.
UroCryo Ablation CLINICAL DATA REVIEW 2015 The information contained in this booklet is being provided as a representative summary only and does not contain all available published data on cryoablation.
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationIntroduction ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access Prostate- specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low- dose- rate brachytherapy
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationClinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center
Advances in Urology Volume 22, Article ID 64263, 8 pages doi:.55/22/64263 Clinical Study Oncologic Outcomes of Surgery in T3 Prostate Cancer: Experience of a Single Tertiary Center D. Milonas, G. Smailyte,
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationHeterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
Cagney et al. BMC Urology (2017) 17:60 DOI 10.1186/s12894-017-0250-2 RESEARCH ARTICLE Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationPSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016
PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationSalvage Cryoablation for Locally Recurrent Prostate Cancer Following Primary Radiotherapy
EUROPEAN UROLOGY 61 (2012) 1204 1211 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Prostate Cancer Salvage Cryoablation for Locally Recurrent Prostate Cancer Following
More informationSalvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer: A Multi-institutional Collaboration
EUROPEAN UROLOGY 60 (2011) 205 210 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Markus Graefen on pp. 211 213 of this issue
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationTiming of Androgen Deprivation: The Modern Debate Must be conducted in the following Contexts: 1. Clinical States Model
Timing and Type of Androgen Deprivation Charles J. Ryan MD Associate Professor of Clinical Medicine UCSF Comprehensive Cancer Center Timing of Androgen Deprivation: The Modern Debate Must be conducted
More informationClinical and biochemical outcomes of men undergoing radical prostatectomy or radiation therapy for localized prostate cancer
Original Article Radiat Oncol J 205;33():2-28 http://dx.doi.org/0.3857/roj.205.33..2 pissn 2234-900 eissn 2234-356 Clinical and biochemical outcomes of men undergoing radical prostatectomy or radiation
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationMATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
More informationthree after the most recent release in These modifications were based primarily on data from clinical, not pathological, staging [1].
. 2010 BJU INTERNATIONAL Urological Oncology PATHOLOGICAL T2 SUB-DIVISIONS AS A PROGNOSTIC FACTOR IN PROSTATE CANCER CASO ET AL. BJUI BJU INTERNATIONAL Pathological T2 sub-divisions as a prognostic factor
More informationRisk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy
RESEARCH ARTICLE Risk Factors for Clinical Metastasis in Men Undergoing Radical Prostatectomy and Immediate Adjuvant Androgen Deprivation Therapy Satoru Taguchi, Hiroshi Fukuhara*, Shigenori Kakutani,
More informationValidation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System
Original Article Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health System Ariel A. Schulman, MD 1 ; Lauren E. Howard, MS 2
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationWhole Gland Cryoablation of Prostate Cancer
Protocol Whole Gland Cryoablation of Prostate Cancer (70179) Medical Benefit Effective Date: 10/01/15 Next Review Date: 07/18 Preauthorization No Review Dates: 02/07, 02/08, 05/09, 01/10, 01/11, 01/12,
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationLong-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence
EUROPEAN UROLOGY 59 (2011) 893 899 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Prostate Cancer Editorial by Bertrand D. Guillonneau and Karim Fizazi on
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationSalvage Brachytherapy After External-Beam Irradiation for Prostate Cancer
Salvage Brachytherapy After External-Beam Irradiation for Prostate Cancer Review Article [1] February 01, 2004 By David C. Beyer, MD [2] The options available for patients with recurrent prostate cancer
More informationSalvage Cryotherapy. Bernard Malavaud MD, PhD, FEBU Institut Universitaire du Cancer Toulouse (France)
Urethra protection Argon decompression -40 /-60 C 17G hollow needles Salvage Cryotherapy Ice all TRUS positioning & monitoring temperature monitoring of the rectal wall ernard Malavaud MD, PhD, FEU Institut
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationThe Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer
55 The Phoenix Definition of Biochemical Failure Predicts for Overall Survival in Patients With Prostate Cancer Matthew C. Abramowitz, MD 1 Tiaynu Li, MA 2 Mark K. Buyyounouski, MD 1 Eric Ross, PhD 2 Robert
More informationRadiation therapy for localized prostate cancer is a main form of therapy
MANAGEMENT OF RADIATION FAILURE IN PROSTATE CANCER Selection of Salvage Cryotherapy Patients Aaron E. Katz, MD, Mohamed A. Ghafar, MD Department of Urology, College of Physicians & Surgeons of Columbia
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationHow to deal with patients who fail intracavitary treatment
How to deal with patients who fail intracavitary treatment A. Heidenreich Department of Urology Non-surgical therapy of PCA IMRT SEEDS IGRT HDR-BRACHY HIFU CRYO LDR - Brachytherapy Author Follow-up bned
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: Results from the Shared Equal
More informationA comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer
ORIGINAL RESEARCH A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer Daniel Taussky, MD; 1 Véronique Ouellet, MD; 2 Guila Delouya,
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationIrreversible Electroporation for the Treatment of Recurrent Prostate Cancer
Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer after prostatectomy, radiation therapy and HiFU R. Schwartzberg, E. Günther, N. Klein, S. Zapf, R. El-Idrissi, J. Cooper, B.
More informationManaging Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps?
Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Michael J Zelefsky, M.D. Professor of Radiation Oncology Chief Brachytherapy Service Department of Radiation Oncology
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationOutcomes of salvage radical prostatectomy following more than one failed local therapy
Original Article - Urological Oncology https://doi.org/10.4111/icu.2018.59.3.152 pissn 2466-0493 eissn 2466-054X Outcomes of salvage radical prostatectomy following more than one failed local therapy Arjun
More informationOncologic Outcome of Robot-Assisted Laparoscopic Prostatectomy in the High-Risk Setting
END-2010-0305-ver9-Engel_1P.3d 09/17/10 2:42pm Page 1 END-2010-0305-ver9-Engel_1P Type: research-article JOURNAL OF ENDOUROLOGY Volume 24, Number 00, XXXX 2010 ª Mary Ann Liebert, Inc. Pp. &&& &&& DOI:
More informationPercent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer
Review Article Percent Gleason pattern 4 in stratifying the prognosis of patients with intermediate-risk prostate cancer Meenal Sharma 1, Hiroshi Miyamoto 1,2,3 1 Department of Pathology and Laboratory
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationImpact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.11.741 Urological Oncology Impact of Adjuvant Androgen-Deprivation Therapy on Disease Progression in Patients with Node-Positive Prostate Cancer
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationJure Murgic 1, Matthew H Stenmark 1, Schuyler Halverson 1, Kevin Blas 1, Felix Y Feng 1,2 and Daniel A Hamstra 1,3*
Murgic et al. Radiation Oncology 2012, 7:127 RESEARCH Open Access The role of the maximum involvement of biopsy core in predicting outcome for patients treated with dose-escalated radiation therapy for
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 1 JANUARY 1 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Results of Long-Term Follow-Up of a Large, Active Surveillance Cohort With Localized Prostate Cancer
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationTreatment of Prostate Cancer Local Recurrence After Whole-Gland Cryosurgery With Frameless Robotic Stereotactic Body Radiotherapy: Initial Experience
Treatment of Prostate Cancer Local Recurrence After Whole-Gland Cryosurgery With Frameless Robotic Stereotactic Body Radiotherapy: Initial Experience Scott Quarrier, 1 Aaron Katz, 2 Jonathan Haas 3 Abstract
More informationPredictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era
ORIGINAL RESEARCH Predictors of time to biochemical recurrence in a radical prostatectomy cohort within the PSA-era Ahva Shahabi, MPH, PhD; 1* Raj Satkunasivam, MD; 2* Inderbir S. Gill, MD; 2 Gary Lieskovsky,
More informationPredictive Models. Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute
Predictive Models Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute Treatment for clinically localized prostate cancer Trade off: Substantial
More informationShort ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy
Short ( 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy Sergey Shikanov, Pablo Marchetti, Vikas Desai, Aria Razmaria, Tatjana Antic, Hikmat Al-Ahmadie*, Gregory
More informationComparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients
Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients R Kuefer 1, BG Volkmer 1, M Loeffler 1, RL Shen 2, L Kempf 3, AS Merseburger 4, JE Gschwend
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationComparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer
Original research Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer Khurram M. Siddiqui, MBBS, MSc, FRCS, FEBU; * Michele Billia, MD; * Andrew Williams,
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationLow risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer
Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationSupported by M. D. Anderson Cancer Center physician investigator funds. We thank Gerald E. Hanks, MD, for help and guidance with this project.
1496 Biochemical and Clinical Significance of the Posttreatment Prostate-Specific Antigen Bounce for Prostate Cancer Patients Treated With External Beam Radiation Therapy Alone A Multiinstitutional Pooled
More informationChapter 6. Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma. Abstract
Chapter 6 Long-Term Outcomes of Radical Prostatectomy for Clinically Localized Prostate Adenocarcinoma Vijaya Raj Bhatt 1, Carl M Post 2, Sumit Dahal 3, Fausto R Loberiza 4 and Jue Wang 4 * 1 Department
More informationProposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy
Proposed prognostic scoring system evaluating risk factors for biochemical recurrence of prostate cancer after salvage radiation therapy Richard J. Lee, Katherine S. Tzou, Michael G. Heckman*, Corey J.
More informationEffective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18
PROVIDENCE HEALTH PLANS MEDICAL (HIFU) (All Lines of Business Except Medicare) Effective Date: 11/1/2018 Section: SUR Policy No: 420 Medical Policy Committee Approved Date: 8/18; 9/18 11/1/18 Medical Officer
More informationProstate Cancer Update 2017
Prostate Cancer Update 2017 Arthur L. Burnett, MD, MBA, FACS Patrick C. Walsh Distinguished Professor of Urology The James Buchanan Brady Urological Institute The Johns Hopkins Medical Institutions Baltimore,
More informationLong-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with Radical Prostatectomy
Jpn J Clin Oncol 2012;42(6)541 547 doi:10.1093/jjco/hys043 Advance Access Publication 28 March 2012 Long-term Oncological Outcome and Risk Stratification in Men with High-risk Prostate Cancer Treated with
More informationJournal of American Science 2018;14(1)
Salvage Radiotherapy Following Radical Prostatectomy: The Proper Timing and Clinical Benefits Mohamed F. Sheta 1, MD, Esam A. Abo-Zena 1, MD and Mohamed H. Radwan 2, MD 1 Department of Clinical Oncology,
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationWhole Gland Cryoablation of Prostate Cancer. Description
Section: Surgery Effective Date: April 15, 2017 Subject: Whole Gland Cryoablation of Prostate Page: 1 of 13 Last Review Status/Date: March 2017 Whole Gland Cryoablation of Prostate Description Cryoablation,
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationCorey C Foster 1, William C Jackson 1, Benjamin C Foster 1, Skyler B Johnson 1, Felix Y Feng 1 and Daniel A Hamstra 1,2*
Foster et al. Radiation Oncology 2014, 9:245 RESEARCH Open Access Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical
More informationOriginal Policy Date
MP 7.01.62 Cryoablation of Prostate Cancer Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return to Medical Policy
More informationExternal validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer
External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer Mathieu Roumiguié, Jean-Baptiste Beauval, Thomas Filleron*,
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 28 OCTOBER 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Predictors of Prostate Cancer Specific Mortality After Radical Prostatectomy or Radiation Therapy Ping Zhou,
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More informationORIGINAL INVESTIGATION. Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans. having prostate cancer, assessment
ORIGINAL INVESTIGATION Impact of Biochemical Recurrence in Prostate Cancer Among US Veterans Edward M. Uchio, MD; Mihaela Aslan, PhD; Carolyn K. Wells, MPH; Juan Calderone, MD; John Concato, MD, MS, MPH
More informationSystems Pathology in Prostate Cancer. Description
Section: Medicine Effective Date: July 15, 2015 Subject: Systems Pathology in Prostate Cancer Page: 1 of 8 Last Review Status/Date: June 2015 Systems Pathology in Prostate Cancer Description Systems pathology,
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation
More informationBJUI. Long-term overall survival and metastasis-free survival for men with prostate-specific antigenrecurrent
21 THE AUTHORS; 21 Urological Oncology DETERMINANTS OF SURVIVAL IN PSA-RECURRENT PROSTATE CANCER AFTER PROSTATECTOMY ANTONARAKIS ET AL. BJUI Long-term overall survival and metastasis-free survival for
More information